ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2017
Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03615235 (APOL1 Long-term Kidney Transplantation Outcomes Network), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Inconsistent values and algorithmic fairness: a review of organ allocation priority systems in the United States.BMC medical ethics · 2024Pooled it
- Genome-wide association study for time to failure of kidney transplants from African American deceased donors.Clinical transplantation · 2020Pooled it
- Advances in HLA and Non-HLA Immune Profiling: Integrating Next-Generation Sequencing and Artificial Intelligence in Transplantation.Annals of laboratory medicine · 2026Review
- APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2025Article
- Optimizing kidney allocation: challenges and solutions.Current opinion in organ transplantation · 2025Review
- Clinical Algorithms and the Legacy of Race-Based Correction: Historical Errors, Contemporary Revisions and Equity-Oriented Methodologies for Epidemiologists.Clinical epidemiology · 2025Review
- Examining Diabetes Status by the Social Determinants of Health Among Adults in Hawai'i.Hawai'i journal of health & social welfare · 2024Article
- Collapsing glomerulopathy is likely a major contributing factor for worse allograft survival in patients receiving kidney transplants from black donors.Frontiers in medicine · 2024Article
- Race-based medicine in the point-of-care clinical resource UpToDate: A systematic content analysis.EClinicalMedicine · 2022Article
- Race Versus Social Determinants of Health in COVID-19 Hospitalization Prediction.American journal of preventive medicine · 2022Article
- Employment status at transplant influences ethnic disparities in outcomes after deceased donor kidney transplantation.BMC nephrology · 2022Article
- Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes.The Journal of clinical investigation · 2021Article
- Deceased-Donor Kidneys: Is Past Performance an Indicator of Future Transplant Success?Kidney international reports · 2021Article
- APOL1 genotyping in kidney transplantation: to do or not to do, that is the question? (pro).Kidney international · 2021Article
- Apolipoprotein L1 and mechanisms of kidney disease susceptibility.Current opinion in nephrology and hypertension · 2021Review
- Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Apolipoprotein L1: role in the evaluation of kidney transplant donors.Current opinion in nephrology and hypertension · 2020Article
- Joint testing of donor and recipient genetic matching scores and recipient genotype has robust power for finding genes associated with transplant outcomes.Genetic epidemiology · 2020Article
- Review
- Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Renal allografts from deceased African American donors with two apolipoprotein L1 gene (APOL1) renal-risk variants fail sooner than kidneys from donors with fewer variants. The Kidney Donor Risk Index (KDRI) was developed to evaluate organ offers by predicting allograft longevity and includes African American race as a risk factor. Substituting APOL1 genotype for race may refine the KDRI. For 622 deceased African American kidney donors, we applied a 10-fold cross-validation approach to estimate contribution of APOL1 variants to a revised KDRI. Cross-validation was repeated 10 000 times to generate distribution of effect size associated with APOL1 genotype. Average effect size was used to derive the revised KDRI weighting. Mean current-KDRI score for all donors was 1.4930 versus mean revised-KDRI score 1.2518 for 529 donors with no or one variant and 1.8527 for 93 donors with two variants. Original and revised KDRIs had comparable survival prediction errors after transplantation, but the spread in Kidney Donor Profile Index based on presence or absence of two APOL1 variants was 37 percentage points. Replacing donor race with APOL1 genotype in KDRI better defines risk associated with kidneys transplanted from deceased African American donors, substantially improves KDRI score for 85-90% of kidneys offered, and enhances the link between donor quality and recipient need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.